Hub71+ Life Sciences has reached its first anniversary with a portfolio of 58 startups that have collectively raised $463 million and generated $138 million in revenue, according to Hub71.
Established with the Department of Health – Abu Dhabi, the Emirates Drug Establishment and the HELM cluster, the specialist ecosystem connects health and life sciences startups with research, clinical development and commercial opportunities in Abu Dhabi.
Its network has expanded to 15 strategic partners, including recent collaborations with Johnson & Johnson and Mediclinic Middle East. The partnerships are intended to provide clinical expertise, mentorship, research support and potential routes to market.
Mediclinic is exploring technologies linked to cancer care, women’s health and chronic disease management, while Johnson & Johnson will engage with startups working on surgical challenges. Hub71 also cited partnerships involving Unilabs Middle East, Takalam and GlycanAge to expand access to digital mental health and preventive healthcare technologies.
Several portfolio companies have advanced their work through the ecosystem. BioSapien secured approvals to move its MediChip cancer treatment platform toward Phase I trials in Abu Dhabi and raised $7.5 million in a round led by Global Ventures. BioTwin partnered with Abu Dhabi Biobank on precision health research, while Nabdh signed an MoU with M42 to scale AI-powered health solutions.
Hub71 said it will continue attracting startups, partners and investment to support the clinical development and commercialisation of life sciences technologies.
Source: Hub71
